150 related articles for article (PubMed ID: 38248110)
1. Hypofractionated Radiotherapy for Hematologic Malignancies during the COVID-19 Pandemic and Beyond.
Antony F; Dubey A; Skrabek P; Tsang LF; Lambert P; Bybel B; Ahmed N
Curr Oncol; 2024 Jan; 31(1):383-393. PubMed ID: 38248110
[TBL] [Abstract][Full Text] [Related]
2. Hypofractionated vs. conventional radiation therapy for stage III non-small cell lung cancer treated without chemotherapy.
Iocolano M; Wild AT; Hannum M; Zhang Z; Simone CB; Gelblum D; Wu AJ; Rimner A; Shepherd AF
Acta Oncol; 2020 Feb; 59(2):164-170. PubMed ID: 31608751
[No Abstract] [Full Text] [Related]
3. Hypofractionated radiotherapy alone with 2.4 Gy per fraction for head and neck cancer during the COVID-19 pandemic: The Princess Margaret experience and proposal.
Huang SH; O'Sullivan B; Su J; Ringash J; Bratman SV; Kim J; Hosni A; Bayley A; Cho J; Giuliani M; Hope A; Spreafico A; Hansen AR; Siu LL; Gilbert R; Irish JC; Goldstein D; de Almeida J; Tong L; Xu W; Waldron J
Cancer; 2020 Aug; 126(15):3426-3437. PubMed ID: 32478895
[TBL] [Abstract][Full Text] [Related]
4. Repeated courses of low-dose 2 × 2 Gy radiation therapy in patients with indolent B-cell non-Hodgkin lymphomas.
Saleh K; Michot JM; Schernberg A; Lazarovici J; Chahine C; Danu A; Khalife-Saleh N; Rossignol J; Ghez D; Martin V; Mazeron R; Fermé C; Boros A; Ribrag V; Girinsky T
Cancer Med; 2020 Jun; 9(11):3725-3732. PubMed ID: 32249547
[TBL] [Abstract][Full Text] [Related]
5. Comparison of hypofractionation and standard fractionation for post-prostatectomy salvage radiotherapy in patients with persistent PSA: single institution experience.
Murgic J; Jaksic B; Prpic M; Kust D; Bahl A; Budanec M; Prgomet Secan A; Franco P; Kruljac I; Spajic B; Babic N; Kruslin B; Zovak M; Zubizarreta E; Rosenblatt E; Fröbe A
Radiat Oncol; 2021 May; 16(1):88. PubMed ID: 33980277
[TBL] [Abstract][Full Text] [Related]
6. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
[TBL] [Abstract][Full Text] [Related]
7. Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomas.
Warlick ED; Tomblyn M; Cao Q; Defor T; Blazar BR; Macmillan M; Verneris M; Wagner J; Dusenbery K; Aurora M; Bachanova V; Brunstein C; Burns L; Cooley S; Kaufman D; Majhail NS; McClune B; McGlave P; Miller J; Oran B; Slungaard A; Vercellotti G; Weisdorf DJ
Biol Blood Marrow Transplant; 2011 Jul; 17(7):1025-32. PubMed ID: 21047561
[TBL] [Abstract][Full Text] [Related]
8. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
Plosker GL; Figgitt DP
Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Treatment Outcome between Hypofractionated Radiotherapy and Conventional Radiotherapy in Postmastectomy Breast Cancer.
Tovanabutra C; Katanyoo K; Uber P; Chomprasert K; Sukauichai S
Asian Pac J Cancer Prev; 2020 Jan; 21(1):119-125. PubMed ID: 31983173
[TBL] [Abstract][Full Text] [Related]
10. Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.
Lowry L; Smith P; Qian W; Falk S; Benstead K; Illidge T; Linch D; Robinson M; Jack A; Hoskin P
Radiother Oncol; 2011 Jul; 100(1):86-92. PubMed ID: 21664710
[TBL] [Abstract][Full Text] [Related]
11. Hypofractionated radiotherapy in ten fractions for postmastectomy patients: a phase II study compared with another hypofractionation schedule with sixteen fractions.
Jiang H; Meng L; Zhang H; Dai X; Zhang Q; Ju Z; Yu W; Ma L
BMC Cancer; 2021 Dec; 21(1):1284. PubMed ID: 34852776
[TBL] [Abstract][Full Text] [Related]
12. Higher-than-expected severe (Grade 3-4) late urinary toxicity after postprostatectomy hypofractionated radiotherapy: a single-institution analysis of 1176 patients.
Cozzarini C; Fiorino C; Deantoni C; Briganti A; Fodor A; La Macchia M; Noris Chiorda B; Rancoita PM; Suardi N; Zerbetto F; Calandrino R; Montorsi F; Di Muzio N
Eur Urol; 2014 Dec; 66(6):1024-30. PubMed ID: 24985964
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of moderately hypofractionated radiotherapy (67.5 Gy in 25 fractions) for prostate cancer confined to the pelvis: a single center retrospective analysis.
Yao L; Shou J; Wang S; Song Y; Fang H; Lu N; Tang Y; Chen B; Qi S; Yang Y; Jing H; Jin J; Yu Z; Li Y; Liu Y
Radiat Oncol; 2020 Oct; 15(1):231. PubMed ID: 33008404
[TBL] [Abstract][Full Text] [Related]
14. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of 10-fraction hypofractionated radiation therapy for non-small cell lung cancer.
Yoo YJ; Kim SS; Song SY; Kim JH; Ahn SD; Lee SW; Yoon SM; Kim YS; Park JH; Jung J; Choi EK
Radiat Oncol J; 2021 Sep; 39(3):202-209. PubMed ID: 34610659
[TBL] [Abstract][Full Text] [Related]
16. Survival Outcomes of Post-mastectomy Breast Cancer Patients Treated with Hypofractionated Radiation Treatment Compared to Conventional Fractionation -a Retrospective Cohort Study.
Raveendran C; Meloot SS; Yadev I
Gulf J Oncolog; 2023 May; 1(42):26-34. PubMed ID: 37283257
[TBL] [Abstract][Full Text] [Related]
17. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial.
Aluwini S; Pos F; Schimmel E; Krol S; van der Toorn PP; de Jager H; Alemayehu WG; Heemsbergen W; Heijmen B; Incrocci L
Lancet Oncol; 2016 Apr; 17(4):464-474. PubMed ID: 26968359
[TBL] [Abstract][Full Text] [Related]
18. Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): acute toxicity results from a randomised non-inferiority phase 3 trial.
Aluwini S; Pos F; Schimmel E; van Lin E; Krol S; van der Toorn PP; de Jager H; Dirkx M; Alemayehu WG; Heijmen B; Incrocci L
Lancet Oncol; 2015 Mar; 16(3):274-83. PubMed ID: 25656287
[TBL] [Abstract][Full Text] [Related]
19. Is There a Role for Hypofractionated Thoracic Radiation Therapy in Limited-Stage Small Cell Lung Cancer? A Propensity Score Matched Analysis.
Zayed S; Chen H; Ali E; Rodrigues GB; Warner A; Palma DA; Louie AV
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):575-586. PubMed ID: 32544575
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated versus conventionally fractionated radiotherapy for patients with localised prostate cancer (HYPRO): final efficacy results from a randomised, multicentre, open-label, phase 3 trial.
Incrocci L; Wortel RC; Alemayehu WG; Aluwini S; Schimmel E; Krol S; van der Toorn PP; Jager H; Heemsbergen W; Heijmen B; Pos F
Lancet Oncol; 2016 Aug; 17(8):1061-1069. PubMed ID: 27339116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
